TNF and Cowden disease: Recent ECCO-ESPGHAN guideline recommends anti-tumor necrosis factor alpha (TNF-α), such as infliximab (IFX), in pediatric CD with a high risk of poor outcome, if serious growth delay is present, or EEN and corticosteroid treatment do not induce remission12.